Lilly reports positive results for Omvoh in Crohn’s disease

Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn’s disease.

The study, called VIVID-2, showed that the majority of patients receiving the drug continuously for two years achieved